• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

GRAS Notices

  • Print
  • Share
  • E-mail

GRN No. 1145

β-lactoglobulin produced by Aspergillus oryzae strain Ao_st0002

Intended Use: Intended for use as a source of protein at levels ranging from 5 to 35 % in meal replacements and supplements, powdered nutritional beverages, electrolyte-sports drinks, high protein performance nutritional beverages, and nutritional bars; milk and milk substitutes, milk drinks, yogurt and fermented milk products, creams and cream substitutes, cheeses, spreads and dips, dairy-based frozen desserts and mixes; desserts and mousses; confections, coatings and fillings; baked goods; salad dressings, minor main entrée sauces; and egg substitutes.
Basis: Scientific procedures
Notifier: Imagindairy Ltd.
Notifier Address: Nahum Het St 7, Tirat Carmel
GRAS Notice (releasable information): GRN 1145 (in PDF) (3.9 MB)
FDA's Letter: Pending